BDSynBio

BDSynBio is a biotechnology company dedicated to reshaping the landscape of the vaccine adjuvant industry. Leveraging its leading chemical synthesis technology platform, the company has been the first in the world to overcome the industrial supply challenge of "golden adjuvant" QS-21. Building on this foundation, BDSynBio is developing an innovative pipeline that includes a variety of novel adjuvants and composite adjuvant systems, while providing global partners with a "one-stop" adjuvant solution ranging from adjuvant screening, formulation development to immunological evaluation, meeting the demand for new adjuvants in vaccine research and production.